Ventyx Biosciences, Inc.

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small-molecule therapies targeting autoimmune, inflammatory, and neurodegenerative diseases. The company's pipeline comprises four primary candidates: VTX958, a selective allosteric tyrosine kinase type 2 inhibitor in clinical development for Crohn's disease; Tamuzimod, a sphingosine 1 phosphate receptor modulator in Phase II trials for ulcerative colitis; VTX2735, a peripheral NLRP3 inflammasome inhibitor for cryopyrin-associated periodic syndrome; and VTX3232, a CNS-penetrant NLRP3 inhibitor currently evaluated in Phase 2a trials for early Parkinson's disease and Phase 2 trials for obesity with cardiovascular risk factors.

As a clinical-stage organization, Ventyx generates no material product revenue. The company operates with 83 full-time employees and maintains headquarters in San Diego, California. Ventyx was incorporated in Delaware in 2018 and is listed on Nasdaq. The company's geographic reach is primarily centered in the United States, though clinical trial operations may extend internationally depending on trial design and regulatory requirements.